Neue WHO-Klassifikation 2022: Harnblasenkarzinom

WHO Classification of Tumours Editorial Board (2022) Urinary and male genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer. https://tumourclassification.iarc.who.int/chapters/36. Zugegriffen: 7. Juli 2022 (WHO classification of tumours series, 5th ed.; vol. 8)

van der Kwast T, Liedberg F, Black PC, Kamat A, van Rhijn BWG, Algaba F, Berman DM, Hartmann A, Lopez-Beltran A, Samaratunga H, Varma M, Cheng L (2022) International society of urological pathology expert opinion on grading of urothelial carcinoma. Eur Urol Focus 8(2):438–446. https://doi.org/10.1016/j.euf.2021.03.017

https://www.awmf.org/uploads/tx_szleitlinien/032-038OLl_S3_Harnblasenkarzinom_2020-04-verlaengert.pdf. Zugegriffen: 17. Juli 2022

Bertz S, Denzinger S, Otto W, Wieland WF, Stoehr R, Hofstaedter F, Hartmann A (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer—evaluation of a large hospital-based single-centre series. Histopathology 59(4):722–732. https://doi.org/10.1111/j.1365-2559.2011.03989.x

Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE (1984) Malignant urachal lesions. J Urol 131(1):1–8. https://doi.org/10.1016/s0022-5347(17)50167-6

Zhong H, Saby G, Kauffman E, Guru K, Azabdaftari G, Xu B (2014) Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder—a study of 22 cases from a single cancer center. Diagn Pathol 9:222. https://doi.org/10.1186/s13000-014-0222-8

Tregnago AC, Epstein JI (2018) Skene’s gland adenokarcinoma: a series of 4 cases. Am J Surg Pathol 42(11):1513–1521. https://doi.org/10.1097/PAS.0000000000001108

Rosenthal DL, Wojcik EM, Kurtycz DFI (2016) The Paris system for reporting urinary cytology. Springer, New York

Hansel DE, Epstein JI, Berbescu E, Fine SW, Young RH, Cheville JC (2007) Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol 31(10):1539–1544. https://doi.org/10.1097/PAS.0b013e318042d596

Kim B, Kim H‑S, Moon KC (2019) Primary renal well-differentiated neuroendocrine tumors: report of six cases with an emphasis on the Ki67 index and mitosis. Diagn Pathol 14(1):12. https://doi.org/10.1186/s13000-019-0791-7

Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG (2005) Small cell carcinoma oft he bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46(1):57–63. https://doi.org/10.1111/j.1365-2559.2004.01980.x

Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BL, Sexton WJ, Gilbert SM (2021) Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J Urol 205(1):100–108. https://doi.org/10.1097/JU.0000000000001325

Neumann HPH, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peçzkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466. https://doi.org/10.1056/NEJMoa020152

van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EMCA, Sleddens HFBM, Derkx P, Rivière J, Dannenberg H, Petri B‑J, Komminoth P, Pacak K, Hop WCJ, Pollard PJ, Mannelli M, Bayley J‑P, Perren A, Niemann S, Verhofstad AV, de Bruïne AP, Eamonn R Maher ER, Tissier F, Méatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, François J, de Herder WW, Vrancken Peeters M‑P FM, van Linge A, Lenders JWM, Gimenez-Roqueplo A‑P, de Krijger RR, Dinjens WNM. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10(8):764–71 DOI https://doi.org/10.1016/S1470-2045(09)70164-0.

Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Lindsey Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley J‑P, van Dooren MF, de Herder WW, Tissier T, Plouin P‑F, van Nederveen FH, Dinjens WNM, Gimenez-Roqueplo A‑P, de Krijger RR (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96(9):E1472–E1476. https://doi.org/10.1210/jc.2011-1043

Zhong M, Tian W, Zhuge J, Zheng X, Huang T, Cai D, Zhang D, Yang XJ, Argani P, Fallon JT, Epstein JI (2015) Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol 39(1):127–131. https://doi.org/10.1097/PAS.0000000000000305

Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, Kundra R, Abeshouse A, Viale A, Cha EK, Hao X, Reuter VE, Rudin CM, Bochner BH, Rosenberg JE, Bajorin DF, Schultz N, Berger MF, Iyer G, Solit DB, Al-Ahmadie HA, Taylor BS (2018) Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res 24(8):1965–1973. https://doi.org/10.1158/1078-0432.CCR-17-2655

Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R, Davidson DD, MacLennan GT, Wang L, Osunkoya AO, Deng Y, Emerson RE, Cheng L (2018) Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common Clonality between small-cell carcinoma of the urinary bladder and Urothelial carcinoma. Eur Urol Focus 4(6):880–888. https://doi.org/10.1016/j.euf.2017.03.007

Zheng X, Zhuge J, Bezerra SM, Faraj SF, Munari E, Fallon JT 3rd, Yang XJ, Argani P, Netto GJ, Zhong M (2014) High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 7:47. https://doi.org/10.1186/s13045-014-0047-7

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A, Siefker-Radtke AO, BLC2001 Study Group. (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 381(4):338–348. https://doi.org/10.1056/NEJMoa1817323

Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O’Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D’Andrea A, Garraway LA, Rosenberg JE (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4(10):1140–1153. https://doi.org/10.1158/2159-8290.CD-14-0623

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF (2018) Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol 36(19):1949–1956. https://doi.org/10.1200/JCO.2017.75.0158